European Medicines Agency validates Kite’s marketing application for second CAR T cell therapy

This article was originally published here

The MAA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which demonstrated an overall response rate of 93 percent, including 67 percent with

The post European Medicines Agency validates Kite’s marketing application for second CAR T cell therapy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply